MedTrace Logo

50% Body Weight Reverses Stature, Lumbar Disc Expansion and Vertebral Compliance by Hyper-Buoyancy Floatation.

NCT05590754 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2022-12-06

No results posted yet for this study

Summary

Study with the aim to see the effect on a space ground analogue , Hyper-Buoyancy Floatation (HBF) on lumbar column and the effect of a supplementary 50% of an axial load.

Conditions

  • Intervertebral Disc Compression
  • Muscle Atrophy
  • Spine Injury

Interventions

DEVICE

Hyper-buoyancy Floatation (HBF)

Participants remained on a waterbed encased within a wooden frame partially (≈50%) filled with water super-saturated with magnesium sulphate at a temperature between 34-36°C regulated by an ultra-thin underbed heater. Participants remained supine and motionless when lay on the HBF except for temporary passive re-orientation to/and back from the prone position for vertebral compliance assessment

DEVICE

Axial Load after 4h of HBF

Participants from observational sat upright in a chair without back support for 15 min before post testing (1G), whilst experimental group participants performed a 30s seated squat with 50% of their body weight (BW) before returning to the upright seated position.

Sponsors & Collaborators

  • Centro Superior de Estudios Universitarios Lasalle

    collaborator UNKNOWN

  • King's College London

    collaborator OTHER

  • Universidad Autonoma de Madrid

    lead OTHER

Principal Investigators

  • David Green, PhD · King's College London

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-12
Primary Completion
2018-07-01
Completion
2022-03-01

Countries

  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05590754 on ClinicalTrials.gov